Corcept Therapeutics Slides 22.6% After Promising Phase 3 Relacorilant Data
Corcept Therapeutics’ shares fell 22.6% over the past month and 42.8% in the past year, with its $3.72 billion market cap pressured by slower-than-expected Korlym sales. The stock was identified as an inflection candidate after promising Phase 3 adrenal cancer data for relacorilant expanded its pipeline beyond Cushing’s syndrome.
1. Investor Letter Highlights Inflection Point
An institutional small-growth strategy nearly doubled its biotech exposure in Q4 and singled out Corcept Therapeutics as being at an inflection point, citing expansion beyond Cushing’s syndrome and the influence of AI and M&A tailwinds on valuation.
2. Stock Performance and Market Cap
Corcept closed February 23 at $35.34, marking a 22.56% decline over one month and a 42.82% drop over 52 weeks, with a current market capitalization of $3.724 billion as investors weighed growth prospects against recent volatility.
3. Pipeline Expansion with Relacorilant Data
Positive Phase 3 results for relacorilant in adrenal cancer drove optimism about the company’s oncology and metabolic pipeline, suggesting potential new revenue streams beyond its flagship Korlym franchise.
4. Sales Growth Concerns
Slower-than-expected Korlym sales growth and uncertainty around the timing of new approvals applied downward pressure on the stock, even as the broader biotech sector attracted renewed interest.